September 11, 2017
Targovax with three oncology posters at ESMO in Spain
Targovax ASA, a clinical stage company focused on immuno-oncology therapies against solid tumors, on Monday revealed that three posters were…
Pharmaceuticals, Biotechnology and Life Sciences
Author: Dino Mustafić
September 8, 2017
Piramal Pharma Solutions names new Chief Operating Officer
India-based Piramal Pharma Solutions (PPS), part of Piramal Enterprises Limited, has named John Fowler as its Chief Operating Officer. In announcing…
September 8, 2017
BMS buys IFM Therapeutics
Bristol-Myers Squibb has completed its previously announced acquisition of IFM Therapeutics, the company said on Thursday.
September 8, 2017
Cemiplimab gets FDA breakthrough therapy designation for certain cell carcinoma
Sanofi and Regeneron Pharmaceuticals, said on Friday that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation status to…
September 8, 2017
Pfenex CFO and CMO leave
USA-based clinical-stage biotechnology company Pfenex Inc. is saying goodbye to its Chief Financial Officer, Dr. Paul Wagner, who has been said on…
September 7, 2017
Novartis’s erenumab can prevent migraine
Novartis’s AMG 334 (erenumab) for migraine prevention in a second phase study reduced monthly migraine days in patients with chronic…
September 7, 2017
Duaklir good for combo option for COPD patients in US
Top-line results from the AstraZeneca’s Phase III AMPLIFY trial for Duaklir met its primary endpoints, demonstrating a statistically-significant improvement in lung function in patients with moderate to very severe stable chronic obstructive pulmonary disease (COPD) compared to each individual component, the company said Thursday. In addition, aclidinium bromide achieved its primary bronchodilation endpoint of demonstrating non-inferiority to tiotropium bromide 18µg once-daily.
September 7, 2017
AZ, Amgen: TSLP is an important mediator of inflammation in severe asthma
AstraZeneca and Amgen on Thursday published results from the PATHWAY Phase IIb trial of tezepelumab that showed a significant reduction in the annual asthma exacerbation rate compared with placebo in patients with severe, uncontrolled asthma. The trial results were published in the New England Journal of Medicine. The PATHWAY trial achieved its primary efficacy endpoint, showing annual asthma exacerbation rate reductions.
September 7, 2017
Verona Pharma expects its new COPD drug to become a valuable addition to drugs commonly used by patients
Verona Pharma revealed the top-line results from its Phase 2a clinical trial, in which RPL554 was dosed in addition to…
September 7, 2017
Akers Biosciences welcome Pamela E. Hibler as North American commercial team VP
Akers Biosciences has appointed Pamela E. Hibler as its North American commercial team Vice President, Sales and Distribution. Hibler has…